News articles about Catalyst Biosciences (NASDAQ:CBIO) have trended somewhat positive recently, Accern Sentiment Analysis reports. The research firm ranks the sentiment of media coverage by monitoring more than 20 million news and blog sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores nearest to one being the most favorable. Catalyst Biosciences earned a media sentiment score of 0.06 on Accern’s scale. Accern also gave news coverage about the biopharmaceutical company an impact score of 45.7739282450341 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the company’s share price in the near future.

These are some of the news articles that may have impacted Accern Sentiment’s scoring:

CBIO has been the subject of several recent research reports. Zacks Investment Research raised Catalyst Biosciences from a “hold” rating to a “buy” rating and set a $5.25 price target for the company in a research report on Wednesday, November 8th. B. Riley initiated coverage on Catalyst Biosciences in a research report on Friday, December 8th. They issued a “buy” rating and a $19.00 price target for the company.

Catalyst Biosciences (NASDAQ CBIO) opened at $13.24 on Monday. The company has a market capitalization of $71.51, a price-to-earnings ratio of -1.01 and a beta of 1.89. Catalyst Biosciences has a 1 year low of $3.11 and a 1 year high of $18.88.

ILLEGAL ACTIVITY WARNING: This report was first reported by TheOlympiaReport and is the sole property of of TheOlympiaReport. If you are accessing this report on another site, it was stolen and reposted in violation of international copyright & trademark law. The original version of this report can be read at https://theolympiareport.com/2017/12/25/catalyst-biosciences-cbio-given-coverage-optimism-score-of-0-06.html.

About Catalyst Biosciences

Catalyst Biosciences, Inc, formerly Targacept, Inc, is a clinical-stage biopharmaceutical company. The Company is focused on creating and developing medicines to address serious medical conditions. The Company focuses its product development efforts in the fields of hemostasis, including the treatment of hemophilia and surgical bleeding, and inflammation, including prevention of delayed graft function (DGF) in renal transplants and the treatment of dry age-related macular degeneration (dry AMD), a condition that can cause visual impairment or blindness.

Insider Buying and Selling by Quarter for Catalyst Biosciences (NASDAQ:CBIO)

Receive News & Ratings for Catalyst Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Catalyst Biosciences and related companies with Analyst Ratings Network's FREE daily email newsletter.